New Developments in Parkinson’s Treatment: ND0612 Takes the Stage

Introduction to ND0612

Mitsubishi Tanabe Pharma America (MTPA) has been at the forefront of Parkinson’s disease research and recently presented their latest findings at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki. The presentations focused on the investigational treatment ND0612, which aims to manage motor fluctuations in Parkinson's patients.

Detailed Presentations at EAN

During the congress, MTPA shared three significant presentations. These included subgroup analyses from the Phase 3 BouNDless trial, a secondary analysis from a Phase 2 study, and details about the infusion site reactions observed in patients receiving ND0612. The findings highlight the potential efficacy and safety of ND0612 for Parkinson’s patients.

Understanding ND0612

ND0612 is an investigational therapy that combines liquid levodopa and carbidopa, delivered continuously through a subcutaneous infusion system. This 24-hour delivery method is designed to help patients maintain steady levels of medication, thereby reducing motor fluctuations and improving quality of life.

Data from the BouNDless Trial

The BouNDless trial is a pivotal Phase 3 study that evaluates the efficacy, safety, and tolerability of ND0612. Subgroup analyses presented at EAN showed promising results, indicating that this treatment could significantly reduce motor fluctuations in Parkinson’s disease patients.

Phase 2 Study Insights

In addition to the BouNDless trial, a Phase 2 study provided further evidence supporting ND0612. This study focused on the onset of efficacy and utilized patient and clinical global ratings to assess the treatment’s impact. The results indicated rapid and sustained improvements in motor function.

Infusion Site Reactions

An analysis of infusion site reactions was also presented at the EAN congress. This analysis characterized the reactions observed in patients undergoing the 24-hour subcutaneous infusion. The findings are crucial in understanding the safety profile of ND0612 and ensuring patient compliance.

MTPA’s Commitment to Parkinson’s Research

Mitsubishi Tanabe Pharma America’s dedication to advancing Parkinson’s disease research is evident in their rigorous clinical trials and ongoing efforts to address unmet needs in the patient community. They aim to provide innovative, effective treatments that improve patient outcomes and quality of life.

About Mitsubishi Tanabe Pharma America, Inc.

Based in Jersey City, MTPA is a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). MTPA focuses on developing and commercializing pharmaceutical products across North America. Their commitment extends to engaging with the scientific community and advancing medical research.

The Role of NeuroDerm, Ltd.

NeuroDerm, Ltd., also a subsidiary of MTPC, is instrumental in the development of ND0612. Based in Israel, NeuroDerm specializes in innovative drug-device combination therapies aimed at improving the lives of patients with central nervous system disorders.

Conclusion

The presentations at the EAN congress highlight the promising future of ND0612 in treating Parkinson’s disease. With ongoing research and collaboration, MTPA continues to lead the way in developing therapies that offer hope to patients and their families.